• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

ABR_Website_Image.jpg

— June 30, 2017

Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members; The Company Confirms its Growth Strategy and R&D Outlook

Read more

— Stock information

@valnevase




















-
— April 18, 2017
Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Read more
— Financial Calendar

August 31, 2017
HY 2017 Financial Statements

November 9, 2017
Q3 2017 Interim Results

See all dates


KOL event in N.Y. on Lyme disease (webcast)



JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs


11th Vaccine Congress
San Diego, US
September 17-20, 2017

World Vaccine Congress Europe
Barcelona, Spain
October 10-12, 2017

21st World Congress and Exhibition on Vaccines, Vaccination & Immunization
Vienna, Austria
November 16-17, 2017


 
Please update your browser...